Greenwood Capital Associates LLC Sells 2,162 Shares of Johnson & Johnson $JNJ

Greenwood Capital Associates LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,821 shares of the company’s stock after selling 2,162 shares during the period. Johnson & Johnson makes up about 1.0% of Greenwood Capital Associates LLC’s investment portfolio, making the stock its 25th largest position. Greenwood Capital Associates LLC’s holdings in Johnson & Johnson were worth $7,916,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 1.4%

Shares of Johnson & Johnson stock opened at $188.51 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.78. The business has a 50-day moving average of $176.18 and a two-hundred day moving average of $162.83. The company has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Bank of America boosted their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday. Morgan Stanley upped their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. UBS Group set a $198.00 price target on Johnson & Johnson in a research report on Friday. Finally, JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $188.88.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.